BSD Medical Corporation Files $50 Million Shelf Registration

The shelf registration statement, when declared effective by the Securities and Exchange Commission, will allow BSD Medical the flexibility to potentially offer and sell from time to time in the future, in one or more public offerings, up to $50 million of common stock, preferred stock, debt securities, warrants or units, or any combination thereof. The specifics of any future offering, along with the prices, terms and the use of proceeds of any such securities offered by BSD Medical, will be determined at the time of any such offering, and will be described in detail in a prospectus supplement filed at the time of any such offering.

Harold Wolcott, President of BSD Medical, said, "We consider this filing to be a proactive measure that will give BSD Medical flexibility in the capital raising process, and will provide the opportunity to potentially move quickly into the capital markets over the next three years if needed."

BSD Medical's shelf registration statement has been filed with the Securities and Exchange Commission but has not yet become effective. The securities registered may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under securities laws of any such state or jurisdiction. An offering of the securities covered by the registration statement will only be by means of a written prospectus supplement.

Copies of the prospectus included in the registration statement may be obtained on the SEC's website at www.sec.gov or by contacting BSD Medical Corporation, Attn: Dennis Gauger, 2188 West 2200 South, Salt Lake City, Utah 84119-1326.

About BSD Medical

BSD Medical is a leading developer of systems used to provide cancer therapies requiring precision-focused heat through RF/microwave technologies. The Company's systems have been designed to kill cancer through heat alone, and as companion therapies to improve the combined results when used along with radiation treatments. For further information visit BSD Medical's website at www.bsdmedical.com.

Statements contained in this press release that are not historical facts, including statements concerning the shelf registration statement and the timing of any offerings under the shelf registration statement, are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including the Company's Form 10-K for its fiscal year ended August 31, 2008 and its Forms 10-Q for the quarters ended November 30, 2008, February 28, 2009 and May 31, 2009. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

SOURCE: BSD Medical Corporation

BSD Medical Corporation, Salt Lake City 
Dennis Gauger, 801-972-5555 
Fax: 801-972-5930 
investor@bsdmc.com